{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Fallopian+Tube&page=4",
    "query": {
      "condition": "Fallopian Tube",
      "page": 4
    },
    "page_size": 10
  },
  "pagination": {
    "page": 4,
    "page_size": 10,
    "total_count": 686,
    "total_pages": 69,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Fallopian+Tube&page=5&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Fallopian+Tube&page=3&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-23T23:31:23.602Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00253383",
      "title": "Early Intervention vs. Standard Palliative Care in Improving End-of-Life Care in Advanced Cancer Patients",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Cancer"
      ],
      "interventions": [
        {
          "name": "counseling intervention",
          "type": "OTHER"
        },
        {
          "name": "educational intervention",
          "type": "OTHER"
        },
        {
          "name": "psychosocial assessment and care",
          "type": "PROCEDURE"
        },
        {
          "name": "quality-of-life assessment",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "OTHER",
        "PROCEDURE"
      ],
      "sponsor": "Dartmouth-Hitchcock Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 329,
      "start_date": "2003-01",
      "completion_date": "2013-09",
      "has_results": false,
      "last_update_posted_date": "2014-12-19",
      "last_synced_at": "2026-10-23T23:31:23.602Z",
      "location_count": 2,
      "location_summary": "Lebanon, New Hampshire • White River Junction, Vermont",
      "locations": [
        {
          "city": "Lebanon",
          "state": "New Hampshire"
        },
        {
          "city": "White River Junction",
          "state": "Vermont"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00253383"
    },
    {
      "nct_id": "NCT07776691",
      "title": "A Study of Raludotatug Deruxtecan With or Without Bevacizumab as First-Line Maintenance Treatment in Non-HRD-Positive Advanced Ovarian Cancer (MK-5909-006, (ENGOT-ov102/GOG-3141/ REJOICE-Ovarian 04)",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Ovarian Cancer",
        "Ovarian Neoplasms",
        "Peritoneal Cancer",
        "Fallopian Tube Cancer"
      ],
      "interventions": [
        {
          "name": "R-DXd",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Bevacizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "Merck Sharp & Dohme LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 802,
      "start_date": "2026-09-18",
      "completion_date": "2034-10-22",
      "has_results": false,
      "last_update_posted_date": "2026-10-21",
      "last_synced_at": "2026-10-23T23:31:23.602Z",
      "location_count": 3,
      "location_summary": "Washington D.C., District of Columbia • Fort Worth, Texas • Tyler, Texas",
      "locations": [
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Fort Worth",
          "state": "Texas"
        },
        {
          "city": "Tyler",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07776691"
    },
    {
      "nct_id": "NCT00799110",
      "title": "Vaccination of Patients With Ovarian Cancer With Dendritic Cell/Tumor Fusions With Granulocyte Macrophage Colony-stimulating Factor (GM-CSF) and Imiquimod",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Ovarian Cancer",
        "Primary Peritoneal Cancer",
        "Fallopian Tube Cancer"
      ],
      "interventions": [
        {
          "name": "GM-CSF",
          "type": "DRUG"
        },
        {
          "name": "Dendritic Cell/Tumor Fusion Vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "imiquimod",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BIOLOGICAL"
      ],
      "sponsor": "Beth Israel Deaconess Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 15,
      "start_date": "2008-05",
      "completion_date": "2025-09",
      "has_results": true,
      "last_update_posted_date": "2026-08-05",
      "last_synced_at": "2026-10-23T23:31:23.602Z",
      "location_count": 4,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00799110"
    },
    {
      "nct_id": "NCT00466960",
      "title": "Sargramostim and Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Advanced Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer That Did Not Respond to Previous Chemotherapy",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Brenner Tumor",
        "Fallopian Tube Cancer",
        "Ovarian Clear Cell Cystadenocarcinoma",
        "Ovarian Endometrioid Adenocarcinoma",
        "Ovarian Mixed Epithelial Carcinoma",
        "Ovarian Mucinous Cystadenocarcinoma",
        "Ovarian Serous Cystadenocarcinoma",
        "Ovarian Undifferentiated Adenocarcinoma",
        "Peritoneal Cavity Cancer",
        "Recurrent Ovarian Epithelial Cancer",
        "Stage III Ovarian Epithelial Cancer",
        "Stage IV Ovarian Epithelial Cancer"
      ],
      "interventions": [
        {
          "name": "sargramostim",
          "type": "BIOLOGICAL"
        },
        {
          "name": "paclitaxel albumin-stabilized nanoparticle formulation",
          "type": "DRUG"
        },
        {
          "name": "laboratory biomarker analysis",
          "type": "OTHER"
        },
        {
          "name": "immunologic technique",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG",
        "OTHER"
      ],
      "sponsor": "University of Washington",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 21,
      "start_date": "2006-05",
      "completion_date": null,
      "has_results": true,
      "last_update_posted_date": "2017-08-28",
      "last_synced_at": "2026-10-23T23:31:23.602Z",
      "location_count": 1,
      "location_summary": "Seattle, Washington",
      "locations": [
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00466960"
    },
    {
      "nct_id": "NCT06342986",
      "title": "Intraperitoneal FT536 in Recurrent Ovarian, Fallopian Tube, and Primary Peritoneal Cancer",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Gynecologic Cancer",
        "Ovarian Cancer",
        "Fallopian Tube Cancer",
        "Primary Peritoneal Cavity Cancer"
      ],
      "interventions": [
        {
          "name": "FT536",
          "type": "DRUG"
        },
        {
          "name": "Fludarabine",
          "type": "DRUG"
        },
        {
          "name": "CY",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Masonic Cancer Center, University of Minnesota",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 3,
      "start_date": "2024-07-11",
      "completion_date": "2027-06-30",
      "has_results": false,
      "last_update_posted_date": "2026-04-02",
      "last_synced_at": "2026-10-23T23:31:23.602Z",
      "location_count": 1,
      "location_summary": "Minneapolis, Minnesota",
      "locations": [
        {
          "city": "Minneapolis",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06342986"
    },
    {
      "nct_id": "NCT04213794",
      "title": "Heated Intra-peritoneal Chemotherapy With Doxorubicin and Cisplatin for Abdominal for Pelvic Tumors in Pediatric Patients",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "EARLY_PHASE1"
      ],
      "conditions": [
        "Malignant Abdominal Neoplasm",
        "Malignant Pelvic Neoplasm",
        "Recurrent Colon Carcinoma",
        "Recurrent Desmoplastic Small Round Cell Tumor",
        "Recurrent Fallopian Tube Carcinoma",
        "Recurrent Gastric Carcinoma",
        "Recurrent Liposarcoma",
        "Recurrent Malignant Mesothelioma",
        "Recurrent Ovarian Carcinoma",
        "Recurrent Primary Peritoneal Carcinoma",
        "Recurrent Rectal Carcinoma",
        "Recurrent Rhabdomyosarcoma",
        "Recurrent Sarcoma",
        "Refractory Colon Carcinoma",
        "Refractory Desmoplastic Small Round Cell Tumor",
        "Refractory Fallopian Tube Carcinoma",
        "Refractory Gastric Carcinoma",
        "Refractory Liposarcoma",
        "Refractory Malignant Mesothelioma",
        "Refractory Ovarian Carcinoma",
        "Refractory Primary Peritoneal Carcinoma",
        "Refractory Rectal Carcinoma",
        "Refractory Rhabdomyosarcoma",
        "Refractory Sarcoma",
        "Resectable Liposarcoma",
        "Resectable Malignant Mesothelioma",
        "Resectable Sarcoma"
      ],
      "interventions": [
        {
          "name": "Cisplatin",
          "type": "DRUG"
        },
        {
          "name": "Cytoreductive Surgery",
          "type": "PROCEDURE"
        },
        {
          "name": "Doxorubicin",
          "type": "DRUG"
        },
        {
          "name": "Hyperthermic Intraperitoneal Chemotherapy",
          "type": "DRUG"
        },
        {
          "name": "Sodium Thiosulfate",
          "type": "DRUG"
        },
        {
          "name": "Computed Tomography",
          "type": "PROCEDURE"
        },
        {
          "name": "Magnetic Resonance Imaging",
          "type": "PROCEDURE"
        },
        {
          "name": "Positron Emission Tomography",
          "type": "PROCEDURE"
        },
        {
          "name": "Biospecimen Collection",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "PROCEDURE"
      ],
      "sponsor": "Mayo Clinic",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "1 Year",
        "maximum_age": "25 Years",
        "sex": "ALL",
        "summary": "1 Year to 25 Years"
      },
      "enrollment_count": 2,
      "start_date": "2019-11-08",
      "completion_date": "2024-10-03",
      "has_results": false,
      "last_update_posted_date": "2025-02-20",
      "last_synced_at": "2026-10-23T23:31:23.602Z",
      "location_count": 1,
      "location_summary": "Rochester, Minnesota",
      "locations": [
        {
          "city": "Rochester",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04213794"
    },
    {
      "nct_id": "NCT03485651",
      "title": "Natera Ovarian Cancer Detection Assay",
      "overall_status": "TERMINATED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Adnexal Mass"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "Natera, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 12,
      "start_date": "2017-12-14",
      "completion_date": "2019-12-31",
      "has_results": false,
      "last_update_posted_date": "2020-02-06",
      "last_synced_at": "2026-10-23T23:31:23.602Z",
      "location_count": 1,
      "location_summary": "Pittsburgh, Pennsylvania",
      "locations": [
        {
          "city": "Pittsburgh",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03485651"
    },
    {
      "nct_id": "NCT06787612",
      "title": "Investigation of Ubamatamab Combination Therapy in Adult Participants With Platinum-Resistant Ovarian Cancer",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Ovarian Cancer",
        "Fallopian Tube Cancer",
        "Primary Peritoneal Cancer"
      ],
      "interventions": [
        {
          "name": "Ubamatamab",
          "type": "DRUG"
        },
        {
          "name": "Bevacizumab",
          "type": "DRUG"
        },
        {
          "name": "Cemiplimab",
          "type": "DRUG"
        },
        {
          "name": "Fianlimab",
          "type": "DRUG"
        },
        {
          "name": "PLD",
          "type": "DRUG"
        },
        {
          "name": "Sarilumab",
          "type": "DRUG"
        },
        {
          "name": "REGN10597",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Regeneron Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 297,
      "start_date": "2025-05-28",
      "completion_date": "2028-06-30",
      "has_results": false,
      "last_update_posted_date": "2026-09-14",
      "last_synced_at": "2026-10-23T23:31:23.602Z",
      "location_count": 21,
      "location_summary": "Birmingham, Alabama • La Jolla, California • Los Angeles, California + 17 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        },
        {
          "city": "Miami",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06787612"
    },
    {
      "nct_id": "NCT03776812",
      "title": "Study of Relacorilant in Combination With Nab-Paclitaxel for Patients With Recurrent Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Recurrent Ovarian Cancer",
        "Recurrent Fallopian Tube Carcinoma",
        "Recurrent Primary Peritoneal Carcinoma"
      ],
      "interventions": [
        {
          "name": "Relacorilant",
          "type": "DRUG"
        },
        {
          "name": "Nab-paclitaxel",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Corcept Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 178,
      "start_date": "2019-04-05",
      "completion_date": "2023-07-12",
      "has_results": true,
      "last_update_posted_date": "2025-10-07",
      "last_synced_at": "2026-10-23T23:31:23.602Z",
      "location_count": 12,
      "location_summary": "Birmingham, Alabama • Scottsdale, Arizona • Denver, Colorado + 6 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03776812"
    },
    {
      "nct_id": "NCT01281254",
      "title": "AMG 386 (Trebananib) in Ovarian Cancer (TRINOVA-2)",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Fallopian Tube Cancer",
        "Ovarian Cancer",
        "Primary Peritoneal Cancer"
      ],
      "interventions": [
        {
          "name": "AMG386 plus PLD",
          "type": "DRUG"
        },
        {
          "name": "Placebo plus PLD",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Amgen",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 223,
      "start_date": "2011-04-18",
      "completion_date": "2017-04-19",
      "has_results": false,
      "last_update_posted_date": "2017-12-02",
      "last_synced_at": "2026-10-23T23:31:23.602Z",
      "location_count": 21,
      "location_summary": "Los Angeles, California • San Francisco, California • Norwalk, Connecticut + 18 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "San Francisco",
          "state": "California"
        },
        {
          "city": "Norwalk",
          "state": "Connecticut"
        },
        {
          "city": "Stamford",
          "state": "Connecticut"
        },
        {
          "city": "Orlando",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01281254"
    }
  ]
}